May 15, 2025

Periodontitis Emerges as Modifiable Risk Factor for AMD

Inflammatory mediators are shared between the conditions.

Conexiant

May 15, 2025

Visual Difficulty, Falls, and Mortality

Recurrent falls were associated with a nearly 50% increased hazard of mortality.

Conexiant

May 08, 2025

Alkeus Presents Data at ARVO on Oral Gildeuretinol for GA

Data were presented from Alkeus Pharmaceuticals’ phase 2 SAGA clinical study in GA secondary to AMD.

Ophthalmology Management

January 01, 2023

Retinal Fluid Fluctuations in the Treatment of Neovascular AMD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 19, 2024

Dosing Proceeds in GA Study

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

New Retinal Physician

January 01, 2025

Clinical Trial Update January/February 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

June 01, 2024

We Need to Talk About GA

Helping patients understand the risks of and treatments for geographic atrophy.

Optometric Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

October 01, 2023

CLINICAL TRIAL DOWNLOAD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician